Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New Model Better Predicts Mortality in HIV-Related DLBCL

Leuk Lymphoma; ePub 2017 Jun 13; Chao, et al

Publish date:: June 21, 2017

A new model combining HIV disease history and tumor markers predicted 2-year mortality better than existing prognostic tools in people with HIV + diffuse large B-cell lymphoma (DLBCL), according to a study involving 80 individuals.

Investigators analyzed the expression of 26 tumor markers in participants with HIV-related DLBCL diagnosed between 1996 and 2007. Among the results:

Expression of cMYC, Ki 67, CD44, EBV, SKP2, BCL6, p53, CD20, and IgM were linked with 2-year mortality.
The final prognostic model included International Prognostic Index; circulating CD4 cell count; history of clinical AIDS; and expression of CD44, p53, IgM, and EBV.

Citation:

Chao C, Silverberg M, Chen L, et al. Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma. [Published online ahead of print June 13, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1334121.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,